Lei Zhang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Lei Zhang has a total of 20 co-authors. Here are the top co-authors by number of shared publications:
- Yuanbao Liu
Jiangsu Province CDC: Jiangsu Province Center for Disease Control and Prevention
2 shared publications Fenyang Tang
Jiangsu Province CDC: Jiangsu Province Center for Disease Control and Prevention
1 shared publication- Fenyang Tang
Department of Expanded Programme on Immunization, Jiangsu Provincial Center for Disease Control and Prevention, Nanjing, 210009, Jiangsu Province, China
1 shared publication Fubao Ma
Jiangsu Province CDC: Jiangsu Province Center for Disease Control and Prevention
1 shared publicationHaiping Chen
Centers for Disease Control and Prevention Division of High Consequence Pathogens and Pathology
1 shared publicationLinyun Luo
China national biotec
1 shared publication
Latest Publications
- Open Access
- 4 November 2020
- Published by Springer Nature in Research Square
Immunogenicity and Safety of Concomitant Administration of 23-valent Pneumococcal Polysaccharide Vaccine and Trivalent Inactivated Influenza Vaccine in Adults Aged 50-70 Years
Background To explore the serological protective effect and to evaluate the safety after combined immunization with 23-valent pneumococcal polysaccharide vaccine and trivalent inactivated influenza vaccine in adults aged 50-70 years.Methods This trial was designed as a single-center, randomized, single-blind, and positive parallel control vaccination study. A total of 1,065 people aged 50-70 years old were observed in Zhenjiang city, Jiangsu Province. Three groups were established, namely, the combined vaccine group (366 people), the pneumonia vaccine group (363 people) and the influenza vaccine group (364 people). The subjects were randomly assigned to each group.Results A total of 1065 subjects were recruited. The noninferiority criterion of GMC ratios was met for all 7 pneumococcal serotypes after concomitant administration when compared with the administration of PPV23 alone. After concomitant administration, the noninferiority criterion of seroconversion rates was met for all influenza subtypes except the influenza H3 virus. The overall incidence of systemic adverse events was 6.67% (71/1065). The most frequently reported systemic adverse events were abnormal body temperature, muscle aches, nausea, and diarrhea. No statistically significant difference in systemic adverse events was found among the three groups.Conclusion The local and systemic response rates in the combination group, pneumonia group and influenza group were similar to those of many similar vaccines, suggesting that the vaccine has good clinical safety. Serological findings from the combination vaccine suggest that it should be encouraged in the future to increase vaccination rates for influenza and pneumonia.Trial Registration: ClinicalTrials.gov NCT02062281 February 13, 2014; Retrospectively registered.
- 4 November 2020
- Published by Springer Nature in Research Square
Open AccessImmunogenicity and Safety of Concomitant Administration of 23-valent Pneumococcal Polysaccharide Vaccine and Trivalent Inactivated Influenza Vaccine in Adults Aged 50-70 Years
Background To explore the serological protective effect and to evaluate the safety after combined immunization with 23-valent pneumococcal polysaccharide vaccine and trivalent inactivated influenza vaccine in adults aged 50-70 years.Methods This trial was designed as a single-center, randomized, single-blind, and positive parallel control vaccination study. A total of 1,065 people aged 50-70 years old were observed in Zhenjiang city, Jiangsu Province. Three groups were established, namely, the combined vaccine group (366 people), the pneumonia vaccine group (363 people) and the influenza vaccine group (364 people). The subjects were randomly assigned to each group.Results A total of 1065 subjects were recruited. The noninferiority criterion of GMC ratios was met for all 7 pneumococcal serotypes after concomitant administration when compared with the administration of PPV23 alone. After concomitant administration, the noninferiority criterion of seroconversion rates was met for all influenza subtypes except the influenza H3 virus. The overall incidence of systemic adverse events was 6.67% (71/1065). The most frequently reported systemic adverse events were abnormal body temperature, muscle aches, nausea, and diarrhea. No statistically significant difference in systemic adverse events was found among the three groups.Conclusion The local and systemic response rates in the combination group, pneumonia group and influenza group were similar to those of many similar vaccines, suggesting that the vaccine has good clinical safety. Serological findings from the combination vaccine suggest that it should be encouraged in the future to increase vaccination rates for influenza and pneumonia.Trial Registration: ClinicalTrials.gov NCT02062281 February 13, 2014; Retrospectively registered.
- Open Access
- 14 November 2018
- Published by Springer Nature in BMC Infectious Diseases
- Vol. 18 (1) , 563
Analysis of sero-epidemiological characteristics of varicella in healthy children in Jiangsu Province, China
In recent years, outbreaks of varicella have continued to occur, and the coverage rate of varicella vaccine in Jiangsu Province, China, remains unclear. This study aims to analyse the levels of immune antibody against varicella and obtain a comprehensive understanding of the varicella attenuated live vaccine (VarV) coverage rate in children aged 1–9 years in Jiangsu Province. From June to October 2016, a cross-sectional survey was conducted to collect 3631 serum samples from healthy children aged 1–9 years in Jiangsu Province. The immunoglobulin G (IgG) antibody levels of varicella were detected by enzyme-linked immunosorbent assay (ELISA). The VarV coverage rate of healthy children was only 43.1% (95% CI: 41.1–44.7%). The seroprevalence after vaccination with a single dose of VarV was only 57.1%, and the overall seropositivity and geometric antibody titre (GMC) were 43.5% and 225.4 mU/ml, respectively. The seropositivity was significantly higher in girls than in boys (χ2 = 18.82, P < 0.001). The difference in seropositivity between the 5–9 age group and 1–4 age group was statistically significant (χ2 = 84.31, P < 0.001). The difference in seropositivity between different regions was statistically significant, with the highest seropositivity in the northern area, 53.7% (χ2 = 35.64, P < 0.001). The seropositivity in the group receiving one dose of VarV was significantly higher than that of the unvaccinated group (χ2 = 205.16, P < 0.001). Linear regression analysis suggested that the GMC of varicella antibodies wanes with the time since vaccination (F = 65.01, P = 0.002). The VarV coverage rate of healthy children in Jiangsu Province was low. Sero-conversion rates were also low after one dose of VarV, and the immune effectiveness of a single dose of VarV was limited. To control the spread of varicella, VarV should be included in the routine immunization program, and strengthened immunization measures for the varicella-susceptible population warrant additional consideration.
- 14 November 2018
- Published by Springer Nature in BMC Infectious Diseases
- Vol. 18 (1) , 563
Open AccessAnalysis of sero-epidemiological characteristics of varicella in healthy children in Jiangsu Province, China
In recent years, outbreaks of varicella have continued to occur, and the coverage rate of varicella vaccine in Jiangsu Province, China, remains unclear. This study aims to analyse the levels of immune antibody against varicella and obtain a comprehensive understanding of the varicella attenuated live vaccine (VarV) coverage rate in children aged 1–9 years in Jiangsu Province. From June to October 2016, a cross-sectional survey was conducted to collect 3631 serum samples from healthy children aged 1–9 years in Jiangsu Province. The immunoglobulin G (IgG) antibody levels of varicella were detected by enzyme-linked immunosorbent assay (ELISA). The VarV coverage rate of healthy children was only 43.1% (95% CI: 41.1–44.7%). The seroprevalence after vaccination with a single dose of VarV was only 57.1%, and the overall seropositivity and geometric antibody titre (GMC) were 43.5% and 225.4 mU/ml, respectively. The seropositivity was significantly higher in girls than in boys (χ2 = 18.82, P < 0.001). The difference in seropositivity between the 5–9 age group and 1–4 age group was statistically significant (χ2 = 84.31, P < 0.001). The difference in seropositivity between different regions was statistically significant, with the highest seropositivity in the northern area, 53.7% (χ2 = 35.64, P < 0.001). The seropositivity in the group receiving one dose of VarV was significantly higher than that of the unvaccinated group (χ2 = 205.16, P < 0.001). Linear regression analysis suggested that the GMC of varicella antibodies wanes with the time since vaccination (F = 65.01, P = 0.002). The VarV coverage rate of healthy children in Jiangsu Province was low. Sero-conversion rates were also low after one dose of VarV, and the immune effectiveness of a single dose of VarV was limited. To control the spread of varicella, VarV should be included in the routine immunization program, and strengthened immunization measures for the varicella-susceptible population warrant additional consideration.